We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.
- Authors
Zhou, Xueyin; Ren, Ting; Zan, Hongyuan; Hua, Chunyan; Guo, Xufeng
- Abstract
Esophageal cancer ranks as the sixth most common cause of cancer death worldwide. Due to the limited efficacy of conventional therapeutic strategies, including surgery, chemotherapy, and radiotherapy, treatments are still far from satisfactory in terms of survival, prompting the search for novel treatment methods. Immune checkpoints play crucial roles in immune evasion mediated by tumor cells, and successful clinical outcomes have been achieved via blocking these pathways. However, only a small fraction of patients can benefit from current immune checkpoint inhibitors targeting programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated protein-4. Unfortunately, some patients show primary and/or acquired resistance to immune checkpoint inhibitors. Until now, novel immune checkpoint pathways have rarely been studied in esophageal cancer, and there is a great need for biomarkers to predict who will benefit from existing strategies. Herein, we primarily discuss the roles of new immune checkpoints as predictive biomarkers and therapeutic targets for esophageal cancer. In addition, we summarize the ongoing clinical trials and provide future research directions targeting these pathways.
- Subjects
IMMUNE checkpoint proteins; PEMBROLIZUMAB; TUMOR markers; ESOPHAGEAL cancer; DRUG target; IMMUNE checkpoint inhibitors; APOPTOSIS
- Publication
Frontiers in Immunology, 2022, Vol 13, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2022.864202